Related Experiment Video
Updated: Jan 12, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Reduction of C. difficile-associated disease using a multifaceted approach
Numair Damani1, Ruth Montgomery2, Stephen Wallace2
1The Malthouse Surgery, The Charter, Abingdon, UK.
Abstract:
Clostridioides difficile is recognised as the most common cause of healthcare-acquired diarrhoea and is a leading infectious cause of morbidity and mortality. The symptoms vary from mild diarrhoea to fulminating infection, leading to pseudomembranous colitis and death. In 2008, the Southern Health and Social Care Trust (SHSCT) noticed a rise in the number of new episodes of C. difficile infection (CDI). As a result, the SHSCT developed a multifaceted approach to reduce CDI, which decreased CDI episodes in hospitals from February 2009 onwards. The reduction of CDI episodes was noted in patients aged >65, per year, from 164 episodes in 2008-09 to 37 episodes in 2009-10, a 77% reduction within 1 year. The number of episodes of CDI continued to decrease until 2021/2022, a 64% reduction since 2008/09. In summary, the successful implementation of a multifaceted intervention strategy is needed to decrease the incidence of healthcare-acquired CDI.
Related Concept Videos
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

